Orchard Therapeutics plc Gains 33.47%

Orchard Therapeutics plc (ORTX:NASDAQ) rocketted at $6.5, representing a gain of 33.5%. The stock appeared on our News Catalysts scanner on Tue 05 Jan 21 at 08:34 AM in the 'MISCELLANEOUS' category. From Tue 22 Dec 20, the stock recorded 62.50% Up Days and 55.56% Green Days

The stock spiked on Fri 18 Dec 20 at $5.48 with a volume of 3M+, and its share price has been moving sideways in recent weeks.

About Orchard Therapeutics plc (ORTX:NASDAQ)

Orchard Therapeutics PLC is a United Kingdom-based commercial-stage, a fully-integrated biopharmaceutical company. The company is engaged in transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Its gene therapy approach seeks to transform a patient's own, or autologous, HSCs into a gene-modified drug product to treat the patient's disease through a single administration. Orchard Rx is focusing on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, used for the treatment of ADA-SCID five lentiviral product candidates.